NASDAQ, VNDA - Vanda Pharmaceuticals
We are a biopharmaceutical company focused on the development and
commercialization of clinical-stage drug candidates for central nervous system
disorders, with exclusive worldwide commercial rights to three product
candidates in clinical development. We believe that each of our product
candidates will address a large market with significant unmet medical needs by
offering advantages over currently available therapies. Our product portfolio
includes:
? Fiaptatm (iloperidone), a compound for the treatment of schizophrenia and
bipolar disorder. On November 27, 2007 the United States Food and Drug
Administration (FDA) accepted a New Drug Application (NDA) for Fiaptatm for
the treatment of schizophrenia. Acceptance of the NDA confirms that the
application is sufficiently complete for FDA review. ...
Read SEC Filing on NASDAQ.com »